Business Standard

S&P upgrades Glenmark to 'BB' on expectation of conservative debt levels

The outlook is stable reflecting the view that Glenmark will maintain its financial policy such that its FFO-to-debt ratio will remain comfortably above 30%, S&P said

Glenmark Pharmaceuticals
Premium

Glenmark Pharmaceuticals

Abhijit Lele Mumbai
Standard and Poor’s (S&P) has upgraded long-term issuer rating on Glenmark Pharmaceuticals from “BB-” to “BB” on the expectation of conservative debt levels given limited upcoming capital investments and healthy free operating cash flow.

Its debt is likely to decline by about 25 per cent in FY22 (year ending March 31, 2022) given management's commitment to maintaining lower leverage following a recent equity raising at its subsidiary. This is expected to boost the company's ratio of funds from operations (FFO) to debt is expected at 35-40 per cent in FY22.

The outlook is stable reflecting the view that Glenmark will maintain its

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in